To demonstrate a long-term survival benefit without a new trial, Neuvivo hired a research firm to track down patients from the original study. By collecting "last date alive" information in a blinded fashion, they generated statistically significant survival data years after the trial concluded.

Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.

Unlike most trials that avoid patients who failed other therapies, Corvus intentionally included them, considering it a 'stacking deck against yourself'. This high-risk bet, based on their drug's unique mechanism, paid off by showing efficacy in a tough-to-treat population and demonstrating a lack of cross-resistance.

NervGen is expanding its drug's potential by partnering with the Department of Defense. Walter Reed tests it for traumatic brain injury, and the Air Force for hearing loss. This strategy provides non-dilutive funding and validation for new indications, broadening the company's platform with minimal internal R&D spend.

The company's origin was a personal quest by a dentist, Harold Punnett, who discovered promising academic research while trying to help his daughter with a spinal cord injury. He licensed the technology and founded the company, highlighting how mission-driven individuals can be powerful catalysts for commercializing science.

Ipsen is developing a next-generation neurotoxin (IPN10200) engineered to have a longer duration of action than current options. As a recombinant neuromodulator, it integrates better into nerve cells, preventing it from distributing into surrounding tissue. This design simultaneously improves longevity and enhances the safety profile compared to traditional compounds.

Running an unusually long, two-year Phase 2 trial allowed Vera to demonstrate stabilization of GFR, a hard kidney function endpoint. This robust, long-term data was crucial for de-risking their Phase 3 program and ultimately securing a coveted Breakthrough Therapy Designation from the FDA, accelerating their path to market.

While outsiders assume walking is the ultimate recovery goal, NervGen's research reveals that regaining hand function for daily tasks like eating or using a computer is the most vital improvement for patient independence. This highlights the importance of patient-defined quality-of-life endpoints in clinical trials.

Re-analysis revealed the drug's efficacy was concentrated in patients 65 and younger, extending survival by 17.1 months. This effect was missed in the original trials because it was diluted by the non-responsive older population, whose declined immune systems could not fully engage with the treatment.